Companies › Amryt Pharma
1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Metreleptin Leptin receptor agonist | LEPR | Phase 4 | Partial Lipodystrophy | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06484868 | Metreleptin | Phase 4 | Partial Lipodystrophy | Metabolic and endocrine | Feb 2028 |
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.